Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | RHOC | P08134 | 1/20 | 0.49 |
| ▸ | RHOA | P61586 | 1/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CCR1 | P32246 | 4/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | EP300 | Q09472 | 1/20 | 0.45 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL76585 | 1.00 | L3MBTL1 (0.50) | L3MBTL1LMNAPOLBMEN1KMT2A | |
| SCHEMBL76342 | 0.85 | F10 (0.56) | L3MBTL1RHOCRHOACYP2C9CYP2C19 | |
| SCHEMBL76341 | 0.85 | F10 (0.56) | L3MBTL1RHOCRHOACYP2C9CYP2C19 | |
| SCHEMBL77131 | 0.84 | F10 (0.44) | — | |
| SCHEMBL77130 | 0.84 | F10 (0.44) | — | |
| SCHEMBL78321 | 0.83 | F10 (0.59) | POLB | |
| SCHEMBL76300 | 0.81 | F10 (0.67) | POLB | |
| SCHEMBL77199 | 0.80 | F10 (0.40) | POLBTRPV1 | |
| SCHEMBL77198 | 0.80 | F10 (0.40) | POLBTRPV1 | |
| SCHEMBL77197 | 0.79 | F10 (0.51) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256131-A1 | CARBONYL COMPOUNDS | TSAKLAKIDIS CHRISTOS | 2010-10-07 | — | — | US | claimed |
| US-20080003214-A1 | Medicaments Comprising Carbonyl Compounds, And The Use Thereof | MERCK PATENT GMBH (DE) | 2008-01-03 | — | — | US | claimed |
| US-20060183739-A1 | Carbonyl compounds | MERCK PATENT GMBH (DE) | 2006-08-17 | — | — | US | claimed |
| US-8129373-B2 | Carbonyl compounds | MERCK PATENT GMBH (DE) | 2012-03-06 | — | — | US | disclosed |
| US-7906516-B2 | Carbonyl compounds | MERCK PATENT GMBH (DE) | 2011-03-15 | — | — | US | disclosed |
| US-20100256131-A1 | CARBONYL COMPOUNDS | TSAKLAKIDIS CHRISTOS | 2010-10-07 | — | — | US | disclosed |
| US-20080003214-A1 | Medicaments Comprising Carbonyl Compounds, And The Use Thereof | MERCK PATENT GMBH (DE) | 2008-01-03 | — | — | US | disclosed |
| US-20060183739-A1 | Carbonyl compounds | MERCK PATENT GMBH (DE) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256131-A1 | CARBONYL COMPOUNDS | F2, F11, PDHX | L3MBTL1 932/4885LMNA 918/4885POLB 2957/4885 |
| US-20080003214-A1 | Medicaments Comprising Carbonyl Compounds, And The Use Thereof | F2, PDHX, SDHB | L3MBTL1 2025/4885LMNA 626/4885POLB 3094/4885 |
| US-20060183739-A1 | Carbonyl compounds | F2, F11, PDHX | L3MBTL1 932/4885LMNA 918/4885POLB 2957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.